<DOC>
	<DOCNO>NCT01110668</DOCNO>
	<brief_summary>This study assess time-to-disease progression patient advance gastrointestinal stromal tumor ( GIST ) previously treat imatinib ≥600 mg .</brief_summary>
	<brief_title>Evaluation Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor ( GIST )</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Histologically confirm diagnosis GIST unresectable and/or metastatic Radiological confirmation disease progression intolerance imatinib therapy dose At least one measurable site disease CT scan Visit2 WHO Performance Status 0 , 1 2 Visit2 Patients must normal organ , electrolyte , marrow function Visit1 Visit2 Prior treatment nilotinib tyrosine kinase inhibitor except imatinib . Treatment cytotoxic and/or investigational cytotoxic drug ≤ 4 week Prior concomitant malignancy GIST Impaired cardiac function Visit1 2 Patients severe and/or uncontrolled concurrent medical disease Use therapeutic coumarin derivative Use medication prolong QT interval Use CYP3A4 inhibitor Patients undergone major surgery ≤ 2 week prior Visit1 recover side effect surgery Patients receive wide field radiotherapy ≤ 4 week limited field radiation palliation &lt; 2 week prior Visit1 recover side effect therapy Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Unresectable</keyword>
	<keyword>metastatic gastrointestinal stromal tumor</keyword>
	<keyword>disease progression</keyword>
	<keyword>progression-free survival</keyword>
</DOC>